France Respiratory Drug Market 2021-2027: Industry Analysis, Trends, Growth, Opportunities, and Forecast

France respiratory drug market was valued more than $1.3 billion in 2018 and is anticipated to grow at a substantial rate of 6.0% during the forecast period. The rising prevalence of chronic respiratory diseases, increasing geriatric population, and technological advancement are the major factors augmenting the growth of the respiratory drug market in the country. Moreover, the presence of market players in the country is also influencing the market growth of the country. For instance, Air Liquide S.A., in April 2018, acquired a French start-up company EOVE for the extension of service offering of home healthcare activities. In January 2018, the company acquired the respiratory division of Thimar Al Jazirah Company (TAC) for geographical expansion and enter into the Saudi Arabia market. In September 2017, Air Liquide acquired Sogo Sangyo Kabushiki Kaisha for expanding its healthcare business in Japan.

To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/france-respiratory-drug-market

The France respiratory drug market is segmented on the basis of the route of administration, application, and end-user. Based on the route of administration, the market is classified into oral, injectable, and inhalable. Moreover, on the basis of application, the market has been classified into asthma and COPD diseases. The asthma disease application segment dominated the regional market in 2018 and is further estimated to follow the same trend over the forecast period. This is mainly due to the high prevalence of asthma in the country. In addition, based on the end-user, homecare and hospitals and clinics have been analyzed.

Browse for Full Report Description@ https://www.omrglobal.com/industry-reports/france-respiratory-drug-market

Furthermore, the market is characterized by the presence of several manufacturers that are developing and providing respiratory drugs to cater to a wide range of customers within and outside the region. The major players of the France respiratory drug market include Boehringer Ingelheim International GmbH, AstraZeneca PLC, GlaxoSmithKline PLC, Novartis AG, F. Hoffmann-La Roche Ltd., and Teva Pharmaceuticals Industries Ltd. These players adopt various strategies to capitalize on market growth opportunities. Mergers and acquisitions, product launch, geographical expansion, partnerships, and collaborations are the majorly adopted strategies by the market players.

Market Segmentation
France Respiratory Drug Market by Route of Administration
• Oral
• Injectable
• Inhalable

France Respiratory Drug Market by Application
• Asthma
• Chronic Obstructive Pulmonary Disease (COPD)

France Respiratory Drug Market by End-User
• Homecare
• Hospitals and Clinics

Company Profiles
• Air Liquide S.A.
• Aradigm Corp.
• AstraZeneca PLC
• Baxter International Inc.
• Boehringer Ingelheim International GmbH
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline PLC
• Merck & Co.
• Novartis AG
• Omron Healthcare Inc.
• Pfizer Inc.
• Pulmatrix Inc.
• ResMed Corp.
• Savara, Inc.
• Sunovion Pharmaceuticals
• Takeda Pharmaceutical Company Ltd.
• Teva Pharmaceuticals Industries Ltd.

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/france-respiratory-drug-market

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 780-304-0404

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.